TAMs function as immune suppressors by producing inhibitory mixtures of cytokines, presenting tumor-associated antigens in a tolerogenic fashion, directly or indirectly suppressing tumor-recognizing T cells via inhibitory molecules, producing chemokines such as CCL2 and CCL5 that preferentially recruit regulatory T (Treg) cells to the tumor site, and by activating metabolic pathways used predominantly by suppressive macrophages [1]. The gene discussed is CCL5; the disease is neoplasm.